Name: Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Limitations of current therapies
Published: 2026-09-28T12:24:10-04:00

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Limitations of current therapies

5 evidence topics · 5 sources

Frequent injections and monitoring visits

“requires repeated and frequent intravitreal injections of the drug, which are necessary to maintain the therapeutic effect, frequent clinical visits to monitor efficacy and safety, and a significant financial burden associated with high drug costs” (opens the source at this quote in a new tab)

Treatment burden on patients and caregivers

“Approximately half of the patients required caregiver support every visit (37.7%) or occasionally (14.6%)” (opens the source at this quote in a new tab)

Contamination risk specific to repackaged bevacizumab

“Investigation of pharmacy A revealed multiple areas in which practices did not conform to United States Pharmacopeial Convention Chapter 797 standards for compounding sterile preparations or to recommended best practices for repackaging bevacizumab; these deficiencies might have contributed to bevacizumab contamination” (opens the source at this quote in a new tab)

Persistent fibrotic scarring despite treatment

“long-term studies show that smaller and less severe fibrotic scars are not uncommon and develop over time despite optimal treatment.” (opens the source at this quote in a new tab)

Response heterogeneity across agents and patients

“Patients with the minor allele of rs2285714 respond worse to antiangiogenic therapy.” (opens the source at this quote in a new tab)